TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06462794: An Investigational Study of CX-801 as Monotherapy and in Combination With PD1 Inhibition in Participants With Solid Tumors

Sponsor: CytomX Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 121 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06462794 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06462794 Rescue Dossier →